270 related articles for article (PubMed ID: 8111066)
41. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
Nagashima M; Werner M; Wang M; Zhao L; Light DR; Pagila R; Morser J; Verhallen P
Thromb Res; 2000 May; 98(4):333-42. PubMed ID: 10822080
[TBL] [Abstract][Full Text] [Related]
42. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
43. Platelet protease nexin-1, a serpin that strongly influences fibrinolysis and thrombolysis.
Boulaftali Y; Ho-Tin-Noe B; Pena A; Loyau S; Venisse L; François D; Richard B; Arocas V; Collet JP; Jandrot-Perrus M; Bouton MC
Circulation; 2011 Mar; 123(12):1326-34. PubMed ID: 21403095
[TBL] [Abstract][Full Text] [Related]
44. Thrombin Provokes Degranulation of Platelet α-Granules Leading to the Release of Active Plasminogen Activator Inhibitor-1 (PAI-1).
Huebner BR; Moore EE; Moore HB; Stettler GR; Nunns GR; Lawson P; Sauaia A; Kelher M; Banerjee A; Silliman CC
Shock; 2018 Dec; 50(6):671-676. PubMed ID: 29280928
[TBL] [Abstract][Full Text] [Related]
45. RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets.
Udvardy M; Schwartzott D; Jackson K; Posan E; Rak K; McKee PA
Blood Coagul Fibrinolysis; 1995 Jul; 6(5):481-5. PubMed ID: 8589217
[TBL] [Abstract][Full Text] [Related]
46. Effective lysis of model thrombi by a t-PA mutant (A473S) that is resistant to alpha2-antiplasmin.
Robbie LA; Bennett B; Keyt BA; Booth NA
Br J Haematol; 2000 Nov; 111(2):517-23. PubMed ID: 11122093
[TBL] [Abstract][Full Text] [Related]
47. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.
Reilly CF; Fujita T; Hutzelmann JE; Mayer EJ; Shebuski RJ
Circulation; 1991 Jul; 84(1):287-92. PubMed ID: 1905594
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of fibrin(ogen) binding to stimulated platelets by a monoclonal antibody specific for a conformational determinant of GPIIIa.
Ramsamooj P; Doellgast GJ; Hantgan RR
Thromb Res; 1990 Jun; 58(6):577-92. PubMed ID: 2385828
[TBL] [Abstract][Full Text] [Related]
49. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor.
Sakata Y; Loskutoff DJ; Gladson CL; Hekman CM; Griffin JH
Blood; 1986 Dec; 68(6):1218-23. PubMed ID: 3096399
[TBL] [Abstract][Full Text] [Related]
50. Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat.
Reilly CF; Fujita T; Mayer EJ; Siegfried ME
Arterioscler Thromb; 1991; 11(5):1276-86. PubMed ID: 1911713
[TBL] [Abstract][Full Text] [Related]
51. Clot penetration and retention by plasminogen activators promote fibrinolysis.
Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
[TBL] [Abstract][Full Text] [Related]
52. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.
Mutch NJ; Thomas L; Moore NR; Lisiak KM; Booth NA
J Thromb Haemost; 2007 Apr; 5(4):812-7. PubMed ID: 17388801
[TBL] [Abstract][Full Text] [Related]
53. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W
Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665
[TBL] [Abstract][Full Text] [Related]
54. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus.
Carr ME; Carr SL; Hantgan RR; Braaten J
Thromb Haemost; 1995 Mar; 73(3):499-505. PubMed ID: 7667835
[TBL] [Abstract][Full Text] [Related]
55. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
Li XK; Lijnen HR; Nelles L; Van Hoef B; Stassen JM; Collen D
Blood; 1992 Jan; 79(2):417-29. PubMed ID: 1730087
[TBL] [Abstract][Full Text] [Related]
56. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
Parise P; Hauert J; Iorio A; Callegari P; Agnelli G
J Lab Clin Med; 1995 Feb; 125(2):212-21. PubMed ID: 7531212
[TBL] [Abstract][Full Text] [Related]
57. Clot lysis induced by a monoclonal antibody against alpha 2-plasmin inhibitor.
Sakata Y; Eguchi Y; Mimuro J; Matsuda M; Sumi Y
Blood; 1989 Dec; 74(8):2692-7. PubMed ID: 2510836
[TBL] [Abstract][Full Text] [Related]
58. Role of platelet GpIIb/IIIa receptors in the modulation of platelet plasminogen activator inhibitors type-1 (PAI-1) release.
Mousa SA; Bozarth J; Forsythe M; Tsao P; Pease L; Reilly TM
Life Sci; 1994; 54(16):1155-62. PubMed ID: 8152339
[TBL] [Abstract][Full Text] [Related]
59. Local thrombin synthesis and fibrin formation in an in vitro thrombosis model result in platelet recruitment and thrombus stabilization on collagen in heparinized blood.
Wagner WR; Hubbell JA
J Lab Clin Med; 1990 Nov; 116(5):636-50. PubMed ID: 2104522
[TBL] [Abstract][Full Text] [Related]
60. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
